Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/63029
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
2030-12-31
Coleções
- INI - Artigos de Periódicos [3397]
Metadata
Mostrar registro completo
IMMUNOGENICITY AND SAFETY OF HEPATITIS B VIRUS (HBV) VACCINE WITH A TOLL-LIKE RECEPTOR 9 AGONIST ADJUVANT IN HBV VACCINE-NAÏVE PEOPLE WITH HUMAN IMMUNODEFICIENCY VIRUS
Autor(es)
Afiliação
Division of Infectious Diseases. Weill Cornell Medicine. New York, New York, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research in the Department of Biostatistics. Boston, Massachusetts, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research in the Department of Biostatistics. Boston, Massachusetts, USA.
Chulalongkorn University. Faculty of Medicine. Thai Red Cross AIDS Research Centre and CE in Tuberculosis. HIV-NAT. Bangkok, Thailand.
Chiang Mai University. Research Institute for Health Sciences. Chiang Mai, Thailand.
Johns Hopkins University. Division of Infectious Diseases. Baltimore, Maryland, USA.
University of Texas. McGovern Medical School, Houston. Division of Infectious Diseases.Texas, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
University of California San Francisco. Department of Medicine. Division of Gastroenterology and Hepatology. San Francisco, California, USA.
University of Zimbabwe. Faculty of Medicine and Health Sciences. Internal Medicine Unit. Harare, Zimbabwe.
DLH Corporation. Silver Spring, Maryland, USA.
Division of AIDS. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Bethesda, Maryland, USA.
University of Cincinnati College of Medicine. Division of Digestive Diseases. Cincinnati, Ohio, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research in the Department of Biostatistics. Boston, Massachusetts, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research in the Department of Biostatistics. Boston, Massachusetts, USA.
Chulalongkorn University. Faculty of Medicine. Thai Red Cross AIDS Research Centre and CE in Tuberculosis. HIV-NAT. Bangkok, Thailand.
Chiang Mai University. Research Institute for Health Sciences. Chiang Mai, Thailand.
Johns Hopkins University. Division of Infectious Diseases. Baltimore, Maryland, USA.
University of Texas. McGovern Medical School, Houston. Division of Infectious Diseases.Texas, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil.
University of California San Francisco. Department of Medicine. Division of Gastroenterology and Hepatology. San Francisco, California, USA.
University of Zimbabwe. Faculty of Medicine and Health Sciences. Internal Medicine Unit. Harare, Zimbabwe.
DLH Corporation. Silver Spring, Maryland, USA.
Division of AIDS. National Institute of Allergy and Infectious Diseases. National Institutes of Health. Bethesda, Maryland, USA.
University of Cincinnati College of Medicine. Division of Digestive Diseases. Cincinnati, Ohio, USA.
Resumo em Inglês
In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior hepatitis B virus (HBV) vaccination, all 68 participants achieved HBV seroprotective titers after the 3-dose series in the primary analysis. No unexpected safety issues were observed.
Compartilhar